Oncolytics Biotech Inc.
210, 1167 Kensington Crescent NW
T2N 1X7 Calgary, Alberta
Michael Moore, VP Investor Relations and Corporate Communications
Company main phone:
+1 (403) 6707377 Company main fax:
+1 (403) 2830858 Email: [Available with subscription]
|Source of foundation:||Independent foundation|
Corporate description / mission:
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer.
State of ownership: Publicly listed on stock exchange
IPO (year): 1999
- Biotechnology - Therapeutics and Diagnostics
|Primary therapeutic areas:
- Neoplasms / cancer / oncology
- Large biotech & big pharma
- Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Description of products:
Special IP situation:
Oncolytics have more than 396 patents issued globally, including more than 49 in the U.S. and 21 in Canada, as well as over 29 applications pending worldwide.
|Market cap. / valuation:||CAD 11.90M|
|Money raised to date:||USD 116.27M|
Market capitalization as on 21 Oct 2019.